Clinical Trials Sponsored by Sinovac Life Sciences Co., Ltd.

Total 518 results

Hangzhou Nuochi Life Science Co., Ltd.

Completed

Measuring the Range of Cardiac Magnetic Parameters in Healthy Subjects by Magnetocardiogram

Healthy People

China
Nimble Science Ltd.
IGY Life Sciences

Recruiting

Evaluation of the Microbiome in Multiple Sclerosis

Multiple Sclerosis

Canada
Sinovac Biotech (Hong Kong) Limited

Completed

Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain

COVID-19

China
LG Life Sciences
Kyorin Pharmaceutical Co.,Ltd

Completed

Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder

Overactive Bladder

Korea, Republic of
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Enrolling by invitation

Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines

Varicella

Philippines
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Active, not recruiting

Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province

Varicella

China
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Completed

A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine

Varicella
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Completed

A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children

Varicella

China
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Recruiting

Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus

Varicella

China
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Completed

Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years Old

Mumps

China
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Completed

A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines

Varicella

China
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Enrolling by invitation

An Immunity Persistence Study of Live Attenuated Varicella Vaccine

Varicella

China
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Enrolling by invitation

Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old

Varicella

China
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Completed

A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine

Varicella

China
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Completed

An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization

Varicella

China
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine

Mumps

China
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Completed

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants

Mumps

China
Wave Life Sciences Ltd.

Recruiting

Study of WVE-003 in Patients With Huntington's Disease

Huntington Disease

Canada, Spain, Australia, Denmark, Netherlands, Poland, United Kingdom, France, Germany, Italy
Avacta Life Sciences Ltd

Recruiting

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Soft Tissue Sarcoma | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Biliary Tract Cancer | Oesophageal Cancer | Cancer of Unknown Primary Site

United States, United Kingdom
Tiziana Life Sciences LTD

Withdrawn

A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease

Crohn's Disease
Wave Life Sciences Ltd.

Terminated

Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease (PRECISION-HD2)

Huntington's Disease

United States, Denmark, Canada, Australia, United Kingdom, France, Germany, Poland
Tiziana Life Sciences LTD

Withdrawn

Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS

Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis
Wave Life Sciences Ltd.

Terminated

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Huntington Disease

Denmark, Australia, Canada, France, United Kingdom, Germany, Poland
Tiziana Life Sciences LTD

Completed

Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

Israel, Greece, Italy
Wave Life Sciences Ltd.

Terminated

Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)

Duchenne Muscular Dystrophy

United States, Belgium, United Kingdom, Czechia, Canada, France, Italy, Sweden
CANbridge Life Sciences Ltd.

Completed

A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme

Glioblastoma Multiforme

Taiwan
CANbridge Life Sciences Ltd.

Unknown

CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma

Glioblastoma
Clinical Life Sciences Ltd.

Completed

Effect of Plant Stanol Esters on Blood Lipids

Elevated Blood Lipids

Finland
Tiziana Life Sciences LTD

Not yet recruiting

Milciclib in Combination With Gemcitabine in Advanced NSCLC

NSCLC
Wave Life Sciences Ltd.

Active, not recruiting

Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Duchenne Muscular Dystrophy

Jordan, United Kingdom
Wave Life Sciences Ltd.

Terminated

Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (FOCUS-C9)

ALS | FTD

Canada, Belgium, New Zealand, Netherlands, Australia, Sweden, United Kingdom, Ireland
Tiziana Life Sciences LTD

Terminated

Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy

Malignant Thymoma

United States, Italy
Tiziana Life Sciences LTD

Terminated

Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

Thymic Carcinoma

United States, France, Italy
CANbridge Life Sciences Ltd.

Unknown

To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)

GBM
Wave Life Sciences Ltd.

Not yet recruiting

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD (RestorAATion-2)

Alpha-1 Antitrypsin Deficiency
Tiziana Life Sciences LTD

Recruiting

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Secondary Progressive Multiple Sclerosis

United States
Wave Life Sciences Ltd.

Recruiting

A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) (RestorAATion-1)

Alpha-1 Antitrypsin Deficiency

United Kingdom
CANbridge Life Sciences Ltd.

Recruiting

Phase 2 Study of CAN008 in Subjects With GBM

Newly-diagnosed Glioblastoma

China
Wave Life Sciences Ltd.

Terminated

Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)

ALS | FTD

Netherlands, United Kingdom
Tiziana Life Sciences LTD

Withdrawn

In-patient COVID-19 Study of Intranasal Foralumab

Covid19 | COVID-19 Respiratory Infection | COVID-19 Lower Respiratory Infection
Wave Life Sciences Ltd.

Terminated

Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease (PRECISION-HD1)

Huntington's Disease

Denmark, Canada, Australia, United Kingdom, France, Germany, Poland
Wave Life Sciences Ltd.

Terminated

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Huntington Disease

Denmark, Australia, Canada, France, United Kingdom, Germany, Poland
Tiziana Life Sciences LTD

Withdrawn

Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM

NAFLD | NASH - Nonalcoholic Steatohepatitis | T2DM (Type 2 Diabetes Mellitus)
Wave Life Sciences Ltd.

Completed

Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Belgium, United Kingdom, France, United States, Italy, Canada, Netherlands
CANbridge (Suzhou) Bio-pharma Co., Ltd.

Recruiting

Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease

Gaucher Disease, Type 1 | Gaucher Disease, Type 3

China
Beijing Likang Life Science and Tech Co., Ltd.

Recruiting

Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors

Advanced Solid Tumor

China
Shenyang Sunshine Pharmaceutical Co., LTD.
Navitas Life Sciences GmbH

Terminated

Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study) (BEAT_001)

Renal Anaemia

Thailand
Ivy Life Sciences, Co., Ltd
Tri-Service General Hospital

Unknown

Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy

Liver Cancer | HepatoCellular Carcinoma

Taiwan
Shenyang Sunshine Pharmaceutical Co., LTD.
Navitas Life Sciences GmbH

Completed

Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study) (BEAT_002)

Renal Anemia

Thailand, Russian Federation
Meril Life Sciences Pvt. Ltd.

Recruiting

Myval Global Study of Myval™ THV Series Implanted in Patients With Native Severe Aortic Valve Stenosis.

Aortic Valve Stenosis

Slovenia, Spain, Turkey, Italy, Netherlands, Estonia, Poland

Clinical Trials Sponsored by Sinovac Life Sciences Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations